Blog

Sumanta K. Pal: Examining docetaxel, apalutamide and radiotherapy in PSA recurrent prostate cancer

Photo taken from Tian Zhang/Twitter

Jul 10, 2024, 07:36

Sumanta K. Pal: Examining docetaxel, apalutamide and radiotherapy in PSA recurrent prostate cancer

Sumanta K. Pal shared on X:

“Congrats Tian Zhang and team on this terrific paper in European Urology Oncology examining docetaxel, apalutamide and radiotherapy in PSA recurrent prostate cancer!”

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial

Authors: Tian Zhang, Lauren Howard, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart A. Frizzell, Luke Nordquist, Julia Rasmussen, Colleen Riggan, Marco Reyes, Catrin Davies, Steven R. Gray, Carly R. Newman, Escarleth Fernandez, Sundhar Ramalingam, Michael R. Harrison, Daniel J. George, Yuan Wu, Andrew J. Armstrong

Sumanta K. Pal

Source: Sumanta K. Pal/X

Andrew J. Armstrong Bart A. Frizzell Bridget F. Koontz cancer Carly R. Newman Catrin Davies Colleen Riggan Daniel J. George Escarleth Fernandez European Urology Oncology Himanshu Nagar Julia Rasmussen Lauren Howard Luke Nordquist Marco Reyes Michael R. Harrison OncoDaily Oncology prostate cancer radiotherapy Rhonda L. Bitting Scott T. Tagawa Steven R. Gray Sumanta K. Pal Sundhar Ramalingam Tian Zhang Yuan Wu

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer